Drug Approval | June 17, 2024
Alembic announces USFDA final approval for Icatibant injection
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Subscribe To Our Newsletter & Stay Updated
